LONDON, March 4, 2026 /PRNewswire/ -- The "Structural Heart Devices Market – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032" report has been added to the Credence Research Inc. offering.

The global Structural Heart Devices Market was valued at USD 5.21 billion in 2018, reached USD 6.68 billion in 2024, and is anticipated to reach USD 12.93 billion by 2032, registering a CAGR of 8.65% during the forecast period. The market's growth reflects rising structural heart disease prevalence, expanding clinical indications for transcatheter therapies, and strong physician and patient preference for minimally invasive procedures that improve recovery outcomes.

Key Takeaways:

• Rising prevalence of valvular heart disease and congenital heart defects is increasing demand for advanced structural heart interventions across aging populations.
• Minimally invasive transcatheter procedures especially TAVR continue to accelerate adoption due to faster recovery, lower procedural risk, and broader eligibility across risk categories.
• Ongoing innovation in transcatheter heart valves, delivery systems, and closure devices, supported by integrated imaging and navigation technologies, is improving procedural precision and outcomes.
• North America leads with ~40.8% share in 2024, supported by advanced cardiac care infrastructure and higher procedure volumes, while Asia Pacific is the fastest-growing region with ~10.0% CAGR driven by expanding healthcare investment and access.

Scope & Segmentation – Structural Heart Devices Market

The report provides a comprehensive analysis of the global Structural Heart Devices Market, covering revenue forecasts from 2024 to 2032. It evaluates market drivers, trends, challenges, competitive landscape, and regional dynamics across transcatheter and surgical device categories. The study assesses innovation in transcatheter valve replacement and repair, expanding regulatory approvals, clinical evidence development, and the role of advanced imaging and navigation technologies in improving procedural safety and effectiveness.

The structural heart devices market is segmented based on product, procedure, end-use, and geography.

• By Product, the market includes Heart Valve Devices (Surgical Heart Valves, Transcatheter Heart Valves), Annuloplasty Rings, Occluders & Delivery Systems, and Other Products.
• By Procedure, the market includes Replacement Procedures (SAVR, TAVR, TMVR, Others) and Repair Procedures (LAAC, TMVr, TTVr, Valvuloplasty, Others).
• By End-use, the market includes Hospitals, Ambulatory Surgical Centers, Cardiac Catheterization Labs, and Other End Use.
• By Geography, the market is analyzed across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, with country-level coverage including the U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, China, Japan, India, South Korea, Southeast Asia, Brazil, Argentina, GCC countries, and South Africa.

Request your sample report today & start making informed decisions powered by Credence Research Inc.! - https://www.credenceresearch.com/report/structural-heart-devices-market

Why This Report Matters

• This report delivers a detailed view of a high-impact cardiovascular devices segment, with the market projected to nearly double by 2032, supported by strong transcatheter procedure momentum.
• It helps decision-makers evaluate how TAVR expansion, transcatheter mitral/tricuspid innovation, and closure device adoption are reshaping structural heart care pathways.
• The study provides regional insights across major markets and emerging economies, helping manufacturers and stakeholders prioritize investments, partnerships, and expansion strategies.
• For CXOs, investors, hospitals, and device innovators, this report offers actionable intelligence on competitive positioning, procedure trends, regulatory dynamics, and growth opportunities.

Market Overview:

• Industry Landscape and Value Chain Assessment
• Supply-Side Evaluation
• Demand-Side Evaluation
• Stakeholder Mapping
• Porter's Five Forces Review
• PESTLE Environment Assessment
• Market Forecast and Future Direction
• Short-Term Forecast (0–2 Years)
• Mid-Term Forecast (3–5 Years)
• Long-Term Forecast (5–10 Years)
• Market Entry and Expansion Strategy

Market Insights:

• Customer and End-User Analysis
• Customer Experience Comparison
• Growth Opportunity Assessment
• Channel and Distribution Review
• Pricing Movement Analysis
• Regulatory and Compliance Review
• Sustainability and ESG Assessment
• Risk and Disruption Analysis
• Investment Return and Cost Evaluation

Key Attributes

Regional Growth Reflects Procedure Adoption and Healthcare Capacity

• North America holds the largest share of the structural heart devices market, accounting for approximately 40.8% of the global market in 2024. The regional market size reached USD 2.73 billion in 2024 (up from USD 2.15 billion in 2018) and is projected to reach USD 5.30 billion by 2032, expanding at a CAGR of 8.7%. Advanced hospital infrastructure, robust adoption of transcatheter therapies, and higher procedure volumes support regional dominance.
• Europe follows with approximately 24.6% share in 2024, rising from USD 1.33 billion in 2018 to USD 1.64 billion in 2024, and is projected to reach USD 2.97 billion by 2032 at a CAGR of 7.7%. Strong cardiac centers, supportive reimbursement structures, and rising valvular disease prevalence contribute to steady growth.
• Asia Pacific is the fastest-growing region with ~10.0% CAGR and approximately 21.9% share in 2024. The market expanded from USD 1.09 billion in 2018 to USD 1.47 billion in 2024 and is expected to reach USD 3.15 billion by 2032, driven by expanding access, growing healthcare investment, and increasing adoption of minimally invasive procedures in major countries including China, Japan, and India.

Market Challenges Include High Costs, Regulatory Complexity, and Procedural Risk

Despite strong growth prospects, the market faces constraints from the high cost of devices and procedures, particularly transcatheter interventions that require expensive implants, specialized equipment, and skilled operators. Cost sensitivity and reimbursement limitations may restrict adoption in developing markets.

The market also faces stringent and time-intensive regulatory pathways, requiring robust clinical evidence, long trial cycles, and significant R&D investment. Approval delays can slow market entry and limit near-term expansion.

In addition, procedural and device-related complications including leakage, incorrect placement, and device malfunction remain concerns. Continued design improvements and standardized operator training are essential to expand adoption and sustain long-term growth.

Future Outlook

The Structural Heart Devices Market is poised for sustained growth through 2032, supported by the continued expansion of transcatheter procedures, broader clinical indications, and rapid technology innovation in valves, closure devices, and delivery systems.

Integration of imaging and navigation tools will continue improving accuracy and outcomes, while emerging markets will play a larger role as healthcare systems expand access to advanced cardiac interventions. As clinical adoption spreads beyond high-risk cohorts, structural heart therapies will remain central to the evolution of minimally invasive cardiovascular care.

Competitive Landscape

The structural heart devices market remains highly competitive, with leading companies focusing on product innovation, strategic partnerships, acquisitions, and geographic expansion. Major players including Abbott, Medtronic, Boston Scientific, Edwards Lifesciences, and LivaNova continue to invest in transcatheter platforms and expanded indications, while other companies strengthen niche capabilities and regional penetration across fast-growing markets.

Key Player Analysis

• Abbott;
• AtriCure;
• BIOMERICS;
• Boston Scientific;
• BRAILE;
• CryoLife;
• Edwards;
• JENAVALVE;
• LEPU MEDICAL;
• LivaNova;
• Medtronic;
• NUMED

Recent Industry Developments

• In July 2024, Edwards Lifesciences announced agreements to acquire JenaValve Technology (transcatheter treatment of aortic regurgitation) and to acquire Endotronix (heart-failure management solutions), positioning both as expansions of its structural heart portfolio.
• In August 2024, Edwards Lifesciences acquired JC Medical from Genesis MedTech, adding JC Medical's transcatheter aortic valve replacement technology aimed at native aortic regurgitation, and also made an additional equity investment of $25 million.

Download Sample - https://www.credenceresearch.com/report/structural-heart-devices-market 

Related Reports –

Congestive Heart Failure Treatment Devices Market https://www.credenceresearch.com/report/congestive-heart-failure-treatment-devices-market

Prosthetic Heart Valves Market https://www.credenceresearch.com/report/prosthetic-heart-valves-market

Transcatheter Heart Valve Replacement Market https://www.credenceresearch.com/report/transcatheter-heart-valve-replacement-market

Structural Heart Devices Market https://www.credenceresearch.com/report/structural-heart-devices-market

Cardiac Surgery and Heart Valve Devices Market https://www.credenceresearch.com/report/cardiac-surgery-and-heart-valve-devices-market

At-Home Heart Health Testing Market https://www.credenceresearch.com/report/at-home-heart-health-testing-market

Flea Tick and Heartworm Products Market https://www.credenceresearch.com/report/flea-tick-and-heartworm-products-market

Heart Valve Devices Market https://www.credenceresearch.com/report/heart-valve-devices-market

Heart Failure Drugs Market https://www.credenceresearch.com/report/heart-failure-drugs-market

Heart Rate Monitor Market https://www.credenceresearch.com/report/heart-rate-monitor-market

About Us

Credence Research Inc is a global market intelligence and consulting firm founded in 2015. It delivers deep market insights, quantitative analysis, and strategic guidance to business leaders, investors, governments, NGOs, and non-profit groups worldwide. The company helps organizations evaluate markets, understand trends, reduce risk, and make data-driven decisions that support growth and competitive strategy. Credence Research is known for rigorous research methods and comprehensive analytics.

The firm produces detailed reports covering market size, forecasts, growth drivers, trends, and competitive landscapes across many industries. Each report often includes frameworks like PESTLE and Porter's Five Forces to give a complete view of market dynamics and future potential. Credence Research also provides tailored consulting services, due diligence support, go-to-market planning, and pre-IPO research to strengthen client strategies and investment narratives. Its insights come from both primary and secondary research, expert interviews, and advanced data modelling. The firm's client base spans Europe, the Americas, Asia-Pacific, and the Middle East/Africa.

To find out more, visit www.credenceresearch.com or follow us on X.com, LinkedIn and Facebook

Contact Us –

Credence Research Inc,

Tower C-1105, S 25,

Akash Tower,

Vishal Nagar,

Pimple Nilakh, Haveli,

Pune – 411027, India

USA: +1-888-600-6441

Email: sales@credenceresearch.com 

Visit Our Website: https://www.credenceresearch.com/

Logo - https://mma.prnewswire.com/media/2562161/Credence_Research_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/structural-heart-devices-market-to-reach-usd-12-93-billion-by-2032-driven-by-rapid-adoption-of-tavr-and-minimally-invasive-transcatheter-therapies--credence-research-302704384.html

Die Schweiz hat Überflugrechte für mehrere US-Militärmaschinen im Zusammenhang mit den jüngsten Angriffen auf den Iran nur teilweise gewährt und dabei ihre Neutralität demonstrativ betont. Der Bundesrat lehnte zwei Gesuche für Aufklärungsflüge ab, während er einen Wartungsflug sowie zwei Transportflüge billigte. Nach Angaben der Regierung in Bern verstieß die beantragte Nutzung des Schweizer Luftraums durch US-Aufklärungsflugzeuge gegen die Vorgaben des Neutralitätsrechts, wonach militärisch relevante Flüge von Konfliktparteien über das Territorium eines neutralen Staates untersagt sind.

Hintergrund sind seit Ende Februar zunehmende Spannungen im Nahen Osten, seit die USA und Israel den Iran ins Visier genommen haben. Seither gehen beim Bundesamt für Zivilluftfahrt (BAZL) vermehrt Anfragen für Überflüge von US-Staats- und Militärmaschinen ein. Die Behörde prüft diese in Abstimmung mit dem Aussendepartement, dem Verteidigungsministerium sowie dem Wirtschaftsdepartement auf Basis der luftrechtlichen Souveränitätsregeln. In politisch heiklen Fällen entscheidet der Bundesrat selbst. Humanitäre und medizinische Flüge, etwa zur Evakuierung von Verwundeten, sowie klar konfliktunabhängige Missionen bleiben nach Regierungsangaben grundsätzlich zulässig.

Das BAZL bestätigte, dass zwei US-Gesuche seit Beginn der jüngsten Eskalation aus verfahrenstechnischen Gründen nicht bewilligt wurden, weil die notwendigen Abklärungen nicht rechtzeitig abgeschlossen werden konnten. Parallel dazu befasst sich die Landesregierung mit der Frage, ob die militärischen Auseinandersetzungen zwischen den USA, Israel und dem Iran neutralitätsrechtlich bereits als Krieg einzustufen sind. Dafür müssten bewaffnete Konflikte zwischen Staaten eine bestimmte Dauer und Intensität erreichen, wie der Bundesrat gegenüber dem Parlament ausführte. Eine abschließende Einordnung liegt noch nicht vor.

Eine solche Einstufung hätte weitreichende Folgen für die Schweizer Außen- und Sicherheitspolitik. Würde der Konflikt offiziell als Krieg gewertet, müsste die Schweiz als neutrales Land militärische Überflüge kriegführender Staaten grundsätzlich untersagen und Rüstungsexporte in die betroffenen Länder stoppen. Außenminister Ignazio Cassis betonte vor Medienvertretern die «immerwährende und bewaffnete Neutralität» des Landes, die konsequent angewandt werde. Der Bundesrat werde sich in den kommenden Tagen erneut mit der Frage der Rüstungsexporte befassen, während Anträge für militärische Überflüge weiterhin Einzelfallprüfungen unterzogen werden.